Clinical Trial Update: Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of lenvatinib with iodine therapy for radioactive iodine–sensitive differentiated thyroid cancer has terminated; results posted previously.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Thyroid Follicular Carcinoma
• Thyroid Papillary Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Emory University | Conditions: Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-11-10